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ABSTRACT
As a part of an international study on the molecular analysis of Diffuse Large 
B-cell Lymphoma (DLBCL), a robust protocol for gene expression analysis from 
RNA extraction to qRT-PCR using Formalin Fixed Paraffin Embedded tissues was 
developed. Here a study was conducted to define a strategy to validate the previously 
reported 6-gene (LMO2, BCL6, FN1, CCND2, SCYA3 and BCL2) model as predictor of 
prognosis in DLBCL. To avoid variation, all samples were tested in a single centre 
and single platform. This study comprised 8 countries (Brazil, Chile, Hungary, India, 
Philippines, S. Korea, Thailand and Turkey). Using the Kaplan-Meier and log rank test 
on patients (n=162) and two mortality risk groups (with those above and below the 
mean representing high and low risk groups) confirmed that the 6-gene predictor 
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score correlates significantly with overall survival (OS, p<0.01) but not with event 
free survival (EFS, p=0.18). Adding the International Prognostic Index (IPI) shows 
that the 6-gene predictor score correlates significantly with high IPI scores for OS 
(p<0.05), whereas those with low IPI scores show a trend not reaching significance 
(p=0.08). This study defined an effective and economical qRT-PCR strategy and 
validated the 6-gene score as a predictor of OS in an international setting.
INTRODUCTION
Curing cancer has become a global priority. 
Optimizing cure rates requires accurate diagnosis for 
the selection of the most appropriate treatment, and 
increasingly this involves genetic subtyping of the 
disease for both diagnosis and prognostic stratification. 
Global gene expression alteration is common and found 
to be correlated with the clinical outcome of cancer. 
Identification of genes with altered expression level 
provides valuable information regarding the diagnosis, 
prognosis and treatment of cancer. Recently high 
throughput, genome-wide expression profiling (GEP) 
analyses indicated that some of these genes can be used 
as marker genes providing important diagnostic and 
prognostic information about the disease [1, 2].
Diffuse large B-cell lymphoma (DLBCL) is the 
most frequent lymphoma in adults worldwide. Patients 
with DLBCL can be risk-stratified on the basis of their 
clinical characteristics, biological sub classification of 
the tumor based on gene or antigen expression, and speed 
of response to treatment based on positron emission 
tomography (PET) monitoring. Lossos et al. using a 
univariate analysis of microarray GEP data, identified 6 
genes (LMO2, BCL6, FN1, CCND2, SCYA, BCL2) from 
a potentially informative 36 gene panel whose expression 
had been reported to predict survival [3]. By analyzing 
the expression of these 6 genes by RT-PCR in 66 patients 
at the time of diagnosis, they showed that the activation 
status of these genes correlated with patient overall 
survival (OS), and was independent of the International 
Prognostic Index (IPI) score. When this 6-gene data 
was combined with the clinical IPI at diagnosis, a high 
predictive index of outcome was achieved. This resulted in 
a 6-gene model designed to predict outcome in individual 
patients independent of the IPI, which was validated in 
two datasets [4, 5]. However, the risk stratification data 
reported had been generated from Western populations. 
It is unclear how applicable this would be to predicting 
clinical outcomes in non-European, non-US populations 
[6].
As the primary purpose of this project was to inform 
management of DLBCL in middle income countries across 
diverse ethnic populations, the first step of this study 
was to identify an optimum and robust methodology 
from RNA extraction to real-time quantitative reverse-
transcription (qRT-PCR) analysis, for routine cancer 
gene expression profiling. A gene expression analysis 
protocol starts with RNA isolation and extends to the 
analysis of qRT-PCR data. qRT-PCR is the most sensitive 
method for quantifying gene expression. The robustness 
of this technique is directly correlated with the integrity 
and quality of RNA, the choice of detection chemistry 
(hydrolysis probes, fluorescent hairpins or intercalating 
dyes) and methods to analyse the data (relative vs. 
absolute). Thus, a robust gene expression analysis protocol 
from RNA isolation to qRT-PCR is crucial.
To this end, we investigated different methodologies 
for quantifying informative gene expression in DLBCL. 
We used the validated 6-gene model to measure whether 
the methods compared achieved equivalent outputs and 
assessing whether the 6-gene model was applicable in an 
international setting.
RESULTS
RNA isolation
The purity of the extracted RNA from formalin 
fixed paraffin embedded (FFPE) tissues was assessed by 
OD 260/280 with minimum and maximum values 1.52 
and 2.16 respectively. Minimum and maximum RNA 
concentration were determined as 47.29 ng/μl and 4385.38 
ng/μl respectively.
High volume vs low volume cDNA synthesis 
comparisons
The workflow for protocol optimization is illustrated 
(Figure S1). In this study in order to evaluate the impact 
of cDNA synthesis efficiency on the relative quantification 
results two cDNA synthesis protocols were followed. 
The first protocol was the one recommended in the ABI 
High Capacity cDNA Reverse Transcription Kit. The 
synthesis volume of this protocol was 20 μl, which was 
then diluted 10 times with sterile ddH2O. The modified 
protocol synthesis volume is 100 μl. Both cDNA synthesis 
protocols starting RNA amount was 1000 ng. The number 
of samples processed with both protocols and both 
chemistries was shown (Supplementary Tables S1 and S2).
In order to assess the efficiency, reproducibility and 
robustness of these two cDNA synthesis protocols the 
triplicate Ct measurement was analyzed using linear mixed 
models, and using the graphics described in the methods 
section. The high volume cDNA synthesis method 
consistently gave lower Ct with lower variation within the 
triplicates for ABL, BCL2, BCL6, CCND2, FN1, LMO2 
and SCYA3 using the Taqman chemistry (Figure 1A). 
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The delta delta Ct values for the 6 genes and 6-gene scores 
of low and high volume synthesis show that they are 
equivalent after normalizations to the housekeeping gene 
ABL and Raji/NLN (Figure 1B and 1C).
Taqman vs SYBR green comparison
Amplifications of the same targets using Taqman or 
SYBR Green chemistries were compared (Figure S2). The 
Figure 1: Low versus high volume cDNA synthesis. A. High volume (blue) consistently gives lower Ct values than low volume 
(red) for most genes and most samples using Taqman chemistry; B. Normalized delta delta Ct values show that low and high volume 
datasets are equivalent (n=44); C. Positive correlation was observed in samples where both low- and high volumecDNA synthesis was 
applied (p<0.001, n=44).
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SYBR Green and Taqman chemistries with the calculated 
data according to the expression ratio based on efficiency 
corrected Delta Ct [7] using the plasmid standard curve 
efficiency show a good correlation (Figure S2A and S2B); 
the Ct values are concordant between the two chemistries 
(Figure S2C).
Standard curves
Expression ratio based on efficiency corrected Delta 
Ct [7] were separately calculated with the efficiency values 
obtained from the Raji cell line, plasmid and Normal 
Lymph Nodes (NLN) standard curves for the each gene. 
Comparisons of plasmid vs the Raji cell line or plasmid 
vs NLN standard curves were undertaken by plotting one 
measurement against the other, and then using plotting the 
limits of agreement. There was a high agreement between 
the three different templates (Figure S3 and S4). While 
using the standard curve from the serial dilutions of the 
Raji cell line, the standard curve for FN1 and CCND2 
genes could not be generated due to high Ct values (above 
Ct35) because of their low expression in the Raji cell line. 
There was a high compatibility between the Raji cell line 
and plasmid standard curves for the genes BCL2, LMO2, 
BCL6 and SCYA3 (Figures S4A and S4B). In contrast to 
standard curves from the Raji cell line, standard curves 
for the 6 genes were successfully generated from the NLN 
cDNA. There was a high correlation between NLN and 
plasmid standard curves for the six genes (Figures S4C 
and S4D).
Copy number vs Ct based calculation 
comparison
Relative expression was calculated using the same 
data set and three different methods namely: copy number 
ratio, delta delta Ct, Pfaffl’s equation with using the 
efficiency of plasmid DNA [7]. Comparisons show that 
all three methods are concordant (Figure S5). There was 
a high compatibility between Delta Delta Ct and Copy 
number ratio (Figure S5A and S5B). The compatibility 
between Pfaffl’s equation and Copy number ratio is shown 
(Figure S5C and S5D).
Validation of 6-gene model
The ‘mortality predictor’ score as described by 
Lossos et al and modified by Malumbres et al for FFPE 
sections, based on LMO2, BCL6, FN1, CCND2, SCYA3, 
and BCL2, was applied to patients in our study [3]. A 
positive correlation was observed in the predictor score 
where both low and high volume data was available 
(Figure 1C; r2=0.689, p<0.001, n=44). The expanded data 
set incorporating multiple imputational analysis was next 
employed, where the overall-survival returned a hazard 
ratio of 0.35 (95% CI 0.17–0.74). This demonstrates that 
the score predicts relative survival well. The patients 
were ranked according to mortality predictor score and 
were divided in high (n=81), and low risk (n=81) groups 
based on the weighted expression of the 6 genes [8]. The 
6-gene predictor model showed that OS was significantly 
longer in the low risk group as compared to that of the 
high risk (Figure 2A, p<0.01); whereas EFS was not 
statistically significantly different between the two risk 
groups (Figure 2B; p=0.18). To evaluate the prognostic 
value of the 6-gene model we next performed survival 
analysis in patients with high and low IPI scores. The OS 
of high risk vs low patients as defined by the 6-gene score, 
was significantly different in patients defined as high risk 
by the IPI (Figure 3A; p<0.05), but not in low risk IPI 
patients (Figure 3B; p=0.08). No difference was observed 
within our cohort between CHOP versus R-CHOP 
treatment regimens in terms of OS (Figure S6A; p=0.41) 
or EFS (Figure S6B; p=0.66). Furthermore, within the 
R-CHOP treated cohort, we did not observe a significant 
difference between the low- versus high- risk groups in 
terms of OS (Figure S7A; p=0.06) or EFS (Figure S7B; 
p=0.19). Hans algorithm where available are shown in 
Table1; no significant difference was found between GCB 
vs non-GCB in our cohort (OS p=0.65; EFS p=0.92).
DISCUSSION
The aim of this international study was to define a 
robust, sensitive and reproducible strategy to identify the 
expression profile of the 6-gene model and to validate 
the six-gene predictor score for outcome in DLBCL. Due 
to the increasing use of qRT-PCR in the diagnostic and 
prognostic setting and the necessity to use FFPE tissue 
for analysis we have developed a robust protocol. It is 
important to optimize the cDNA synthesis step and to 
note that most manufacturers recommend low volume 
cDNA synthesis method. It would appear that, due to the 
reproducibility of the triplicates and reduced Ct values of 
high volume cDNA synthesis, the high volume synthesis 
is superior to the low volume synthesis using the Taqman 
chemistry (Figure 1). This profile is lost with the SYBR 
Green reactions possibly due to the larger amplicon size. 
This is particularly important when dealing with the low 
quality of RNA we expect from paraffin-derived tissues. 
However, with the NLN derived RNA, which would be 
of good quality, the high volume cDNA consistently gave 
lower Ct values for all of the amplicons tested. However, 
normalizations ensured that the delta delta Ct values and 
6-gene scores were finally equivalent.
The two most commonly used chemistries of 
Taqman and SYBR Green correlate well. The difference 
in cost between these reagents has precluded the use of 
Taqman reagents in resource poor settings; this study 
shows that SYBR Green method can substitute for Taqman 
well. However, the optimal amplicon size for SYBR 
Green is around 300 bp whereas for Taqman it is 100 bp, 
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therefore for FFPE derived degraded RNA Taqman is the 
chemistry of choice both for size and specificity with the 
use of an internal probe.
Standard curves generated from the plasmid and 
cellular derived cDNAs are equivalent and therefore the 
copy number method, which relies on generating a plasmid 
derived standard curve correlates with the delta delta Ct 
and efficiency corrected Ct method. This study shows that 
it is not necessary to clone every target under investigation 
for obtaining relative quantities and comparing data from 
Figure 2: Six-gene model predicts overall survival (OS) in diffuse large B-cell lymphoma (DLBCL) patients treated with 
Rituximab, cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (Oncovin ®), prednisolone (a steroid) 
(R-CHOP) and CHOP chemotherapy within an international multi-centre setting. Kaplan-Meier curves of 162 patients. A. 
show significant extended OS of low risk patients as defined by 6-gene predictor score ( p<0.01; patient numbers Low n=81, High n=81); 
B. show no significant EFS of low risk patients as defined by the 6-gene predictor score (p=0.18; patient numbers Low n=81, High n=81).
Oncotarget83324www.impactjournals.com/oncotarget
different plates; one can use standard curves derived from 
a reference cell line. However, to obtain absolute values, it 
remains necessary to use plasmid derived standard curves. 
At the end of these optimization steps we concluded that 
high volume cDNA synthesis, use of Taqman chemistry 
should be the protocol to follow in especially FFPE 
derived RNA samples. Here in this international study we 
have developed a robust, sensitive and reproducible qRT-
PCR strategy suitable for the limited budgets available in 
middle-income countries, from RNA extraction up to data 
Figure 3: Six-gene predictor model is independent of the International Prognostic Indicator (IPI). A. Significant difference 
is observed in Kaplan-Meier curves of overall survival (OS) based on 6-gene predictor score in high clinical risk patients (IPI score 3-5, 
n=51) (p<0.05); Patient numbers Low n=23, High n=28; B. no significant difference in Kaplan-Meier curves of OS in low clinical risk 
patients (IPI score 0-2, n=111) (p=0.08); Patient numbers Low n=58, High n=53.
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analysis to identify the expression profile of the six gene 
model.
As with the Malumbres study, where FFPE tissue 
was used, this international study returned a significant 
association between the 6-gene predictor score and OS. 
When added to IPI the 6-gene score was significantly 
associated with high IPI score and not low IPI score, 
whereas the Malumbres study was significantly associated 
with low IPI and not high [8]. This suggests that both 
studies would benefit from increased sample size. In an 
international setting involving patients from 8 countries, 
3 continents and different ethnic backgrounds our study 
has demonstrated that the 6 gene score can add some 
prognostic information to patients with a high clinical 
risk index, validating this model as a prognosticator in 
DLBCL, illustrating the utility of molecular expression 
studies.
MATERIALS AND METHODS
Patients
The International Atomic Energy Agency 
(IAEA) sponsored a prospective study of DLBCL in 
countries from 8 United Nations geographical regions. 
Patient samples were obtained from clinical centres 
in the countries detailed in Table 1. The local ethics 
committee approved the study and informed consent 
was obtained from all patients. Consented patients 
with DLBCL (n=162) in Brazil (n=18), Chile (n=27), 
Hungary (n=28), India (n=27), South Korea (n=7), 
Philippines (n=13), Thailand (n=27), and Turkey were 
treated with a mixture of rituximab, cyclophosphamide, 
doxorubicin (hydroxydaunomycin), vincristine (Oncovin 
®), prednisolone (a steroid) (R-CHOP) (83%) or CHOP 
(17%) between 2008 and 2013. Diagnosis was made by 
country representative pathologists and the diagnostic 
criteria was set up in a collaborative meeting (Ankara). 
Hans algorithm was used for immunohistochemical 
subclassification (CD10, Bcl6, MUM1). This method 
and markers are accepted as gold standard and reliable 
for the subclassification. These patients were a subset 
of the cohort of a Coordinated Research Project 
funded by the IAEA where the use of interim PET was 
investigated in order to risk stratify patients [9]. CD20 
immunohistochemistry was performed for all of the cases 
for indication of anti CD20 therapy.
RNA isolation
Total RNA was extracted from FFPE tissues (five 
sections (10 μm thickness) using Qiagen FFPE Rneasy 
Kit (Qiagen Cat #74404, Valencia, CA, USA) with a 
modified deparaffinization step [10]. Briefly, sections 
were deparaffinized by 2 repeated incubations in xylene 
for 10 minutes, followed by 2 repeated incubations in 
100% ethanol for 5 minutes and then were washed with 
distilled water for 30 seconds. After deparaffinization, 
the remaining steps of RNA extraction were followed 
according to the Qiagen FFPE RNeasy Kit manual. All 
RNA samples were analyzed spectrophotometrically on 
a Nanodrop (NanoDrop 1000 Spectrophotometer V3.7, 
Thermo Fisher Scientific Inc, Wilmington, DE, USA).
cDNA synthesis
Two different cDNA synthesis methods were 
evaluated. The integrity of the cDNA templates 
was evaluated using the Fusion Quant® standard 
ABL (reference: CGRS-01-4, Ipsogen, France) and 
subsequently qRT-PCR was carried out on the 7 target 
genes with Taqman and in a subset, SYBR Green 
chemistry (Table S1 and Table S2).
Molecular cloning of the target genes
The target genes (LMO2, BCL6, FN1, CCND2, 
SCYA3) were amplified (primer details in Supplementary 
Table S3) and cloned into the TOPO® vector and 
transformed to chemically competent E.coli cells 
(provided by the Kit) according to the manufacturer’s 
instructions (Invitrogen TOPO TA Cloning Kit Cat 
No.K4510-20, Carlsbad, CA, USA). Plasmid DNA was 
purified with QIAprep Spin Miniprep Kit (Cat No.27104 
Hilden, Germany) according to the manufacturer’s 
instructions. To confirm the cloning, PCR reactions were 
repeated for target genes from plasmid DNA minipreps 
and then sent for sequencing. The BCL-2 plasmid was 
already available [11].
Low volume
1000 ng RNA was used to synthesize using the ABI 
High Capacity cDNA Reverse Transcription Kit (Cat. 
4368813 Foster City, CA, USA) in a total volume of 20 
μl. This cDNA sample was then diluted to 100 μl and 2 
μl (20 ng) is used per each qRT-PCR reaction (according 
to the kit user instructions). Samples from Brazil were 
synthesized only with the low volume protocol.
High volume
1000 ng RNA was used to synthesize using ABI 
High-Capacity cDNA Reverse Transcription in a total 
volume of 100 μl. The reaction volume was equal to 5 
times of the original reaction mix with 1000 ng RNA. 2μl 
(20 ng/μl) cDNA samples directly used per each qRT-PCR 
reaction.
qRT-PCR analysis
Standard curves were prepared from plasmids 
containing cloned target genes (BCL-2, LMO2, BCL6, 
FN1, CCND2, SCYA3) that were amplified (method details 
in supplementary methods information, cloning primer 
details in Table S3 and SYBR green primers in Table 
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S4). Taqman qRT-PCR assays were conducted on a Light 
Cycler 480 (Roche, Mannheim, Germany) platform using 
Life Technologies Applied Biosystems Taqman Gene 
Expression Assays according to the kit user instructions 
(BCR ABL1 Hs99999002_mH, BCL2 Hs00153350_
m1, BCL6 Hs00277037_m, CCND2 Hs00277041_
m1, FN1 Hs00365058_m1, LMO2 Hs00277106_m, 
SCYA3 Hs00234142_m1, TNFRSF9 Hs00155512_m1) 
and TaqMan® Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) Cat. 4304437). 
Expression ratios were calculated based on delta delta Ct: 
R=2(–ΔΔCT) [7].
Copy number of the plasmids
Dilutions were calculated for copy numbers of 
108 – 103 for each of the 8 plasmids [12, 13]. All qRT-
PCRs were undertaken using a 384-plate Roche LC480 
instrument (Roche, Mannheim, Germany) at the Ankara 
University Biotechnology Institute Central Laboratory by 
one investigator. Most of RNA extractions and the cDNAs 
were done at Ankara University by the investigators from 
the participating countries. qRT-PCRs were done from 
plasmid DNAs of the target genes to generate standard 
curves with the Power SYBR® Green PCR Master Mix 
(Life Technologies, Applied Biosystems, Cat.No. 4367659, 
Carlsbad, CA) according to the manufacturer’s instructions.
Formula;
= •N Cplasmid
A
1,07085.1015
N: Copy number (copies/μl)
C plasmid: Concentration of the plasmid DNA 
(μg/μl)
A: Size of the plasmid with insert (bp)
Standard curves
Standard curves were derived from plasmids, Raji 
cell line and a normal lymph node (NLN) pool from FFPE 
Table 1: Patient and treatment details 
 TOTAL
Number of Patients 162
Sex M
83
(51%)
Age at Diagnosis
Median (quartiles)
55
(46,66)
IPI Score 0-1
   2
   3
   4-5
75 (46%)
37 (23%)
33 (20%)
17 (11%)
GCB/non-GCB/unknown
(% non-GCB where known)
56/76/30 (47%)
Mean 2y Outcomes (days)[range]
(95% CI)
OS: 538
[480–596]
EFS: 423
[366–481]
R-CHOP
CHOP
134 (83 %)
28 (17 %)
Chemotherapy
Cycles:  <6
          6
      >6
19 (12 %)
84 (52 %)
59 (36 %)
Consolidation Radiotherapy
Total
(Bulky disease)
(Non-bulky site)
42 (28 %)
(38)
(4)
Number of patients with significant Rx delays or dose reductions
23/100 (23 %)
(48 not known)
rituximab, cyclophosphamide, doxorubicin (Hydroxydaunomycin), vincristine (oncovin ®), prednisolone (a steroid) 
(R-CHOP).
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sections. For plasmids serial dilutions from 108 to 103 
copies were prepared. For the Raji and NLN 6x 10 fold 
serial dilutions were prepared from the original cDNA 
stock (1 μg RNA in 100 μl synthesis reaction for high 
volume and 1 μg RNA in 20 μl for low volume). qRT-PCR 
reactions were performed.
SYBR green reactions
Target genes BCL2, BCL6, CCND2, FN1, LMO2, 
SCYA3 and ABL qRT-PCR analysis were conducted on a 
Light Cycler 480 platform using ABI Power SYBR Green 
PCR Master Mix (Applied Biosystems Cat. 4367659, 
Foster City, CA, USA). Primer sequences, annealing 
temperatures and amplicon sizes for the seven target 
genes and ABL housekeeping gene [14, 15] are listed in 
Supplementary Table S3. Briefly PCR conditions are 94ºC 
for 3 min, 30 cycles of 94ºC 30 sec, appropriate annealing 
temperature for 30 sec, and 72ºC for 30 sec. Followed by 
a melting program.
Expression ratios and statistical analysis
Relative quantifications were carried out using three 
different approaches detailed below and comparative 
analyses were undertaken.
Expression Ratio Based on Normalized Copy 
Numbers [16]
=R Patient Target Gene Copy No
Patient ABL Copy No
Control Target Gene Copy No
Control ABL Copy No
Expression Ratio Based on Efficiency Corrected 
Delta Ct [7]
R
A
ControlCt PatientCt
ControlCt PatientCt
E
E
=
−( )
−( )
Target Gene
BL
E: Efficiency
Ct: threshold cycle
Expression Ratio Based on Efficiency Delta Delta 
Ct [17]
R CT= −( )2 ∆∆
Validation of the 6-gene model
As an independent study with measurements on 
the six-genes score used by Lossos et al and modified by 
Malumbres et al (LMO2, BCL6, FN1, CCND2, SCYA3 
and BCL2) validation of the scores was performed [3]. 
For the prognostic score analysis samples with ABL Ct 
values >37 were not included. This cut off was determined 
from standard curves generated with target genes cloned 
into plasmids by running an absolute quantification. Thus, 
as seen from the Figure S8 the log copy number of ABL 
of the samples at this low range correlates with ABL Ct. 
Ct 37 corresponds to 9-15 copies, which is within the 
limits of detection for this assay, which has a cut off of 
<3 copies [18–20]. As raw Ct values may vary between 
samples, delta Ct values were compared to FFPE normal 
lymph node samples. The samples acceptance criteria was 
based upon the Minimum Information for Publication 
of Quantitative Real-Time PCR Experiment) (MIQE) 
guidelines [18] as well as the determined PCR efficiency 
for each assay using FFPE NLN for ABL and all six genes 
(all 95.5%-99.5%).
As the original scores were based on data using low 
volume cDNA synthesis, the initial analysis using separate 
multiple imputation of low-volume & high-volume data 
and the Lossos predictor formula was undertaken (n=162 
patients) [3, 21]. The normalized gene-expression values 
were log-transformed (on a base of 2) and the mortality 
predictor score was calculated based on the following 
equation: Mortality Predictor Score = (-0.0273xLMO2) + 
(-0.2103xBCL-6) + (-0.1878xFN1) + (0.0346xCCND2) + 
(0.1888xSCYA3) + (0.5527xBCL-2) [3]. This score was 
categorically ranked which allowed their division into 
two mortality risk groups with those above and below 
the mean representing high and low risk groups [8]. 
Unlike the original Lossos study, where fresh tissue was 
used, the Malumbres method used FFPE tissue, similar 
to this current study. OS was defined as the time interval 
between the date of diagnoses to the date of death or last 
follow-up. Event free survival was defined as the time 
interval between the date of initial diagnosis and date of 
disease progression or death from any cause, whichever 
came first, or date of last follow-up evaluation. Survival 
curves were estimated using the product-limit method 
of Kaplan-Meier and were compared using the log-rank 
test. Multivariate regression analysis according to the Cox 
proportional hazards regression model [22] with OS or 
EFS as the dependent variables, was used to adjust for 
the effect of the Mortality Predictor Score and IPI. The 
t-test or Pearson’s Chi-squared test were used to compare 
the clinical characteristics between the low and high 
risk patient groups of the 6-gene model. p < 0.05 was 
considered significant. Statistical analyses were carried 
out in Stata, GraphPad Prism and SPSS.
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